Lyell Immunopharma (NASDAQ:LYEL) Raised to "Hold" at Wall Street Zen

Key Points

• Lyell Immunopharma has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, indicating a more favorable outlook for the stock.
• HC Wainwright has maintained a "neutral" rating for Lyell Immunopharma and set a price target of $10.00 per share, while the consensus target price remains at $15.00.
• The company's stock recently opened at $11.08 after reporting quarterly earnings that exceeded expectations with an EPS of ($2.89).

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Monday.

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $10.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, June 24th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus target price of $15.00.

Lyell Immunopharma Trading Down 0.2%

NASDAQ:LYEL opened at $11.08 on Monday. The company has a market cap of $212.85 million, a PE ratio of -0.46 and a beta of -0.19. Lyell Immunopharma has a twelve month low of $7.65 and a twelve month high of $32.00. The company's 50 day moving average is $10.44 and its two-hundred day moving average is $10.33.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.80) by $0.91. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative return on equity of 85.58%. As a group, analysts expect that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

A number of hedge funds have recently added to or reduced their stakes in the company. Graham Capital Management L.P. acquired a new position in Lyell Immunopharma during the fourth quarter worth $33,000. Wells Fargo & Company MN lifted its holdings in Lyell Immunopharma by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock valued at $60,000 after purchasing an additional 20,542 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Lyell Immunopharma during the fourth quarter valued at $64,000. Marshall Wace LLP purchased a new position in Lyell Immunopharma during the second quarter valued at $94,000. Finally, AQR Capital Management LLC lifted its holdings in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock valued at $94,000 after purchasing an additional 154,327 shares in the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.